Novack David F 4
4 · DYNAVAX TECHNOLOGIES CORP · Filed Mar 26, 2025
Insider Transaction Report
Form 4
Novack David F
President & COO
Transactions
- Sale
Common Stock
2025-03-24$14.00/sh−10,000$140,000→ 8,078 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-24−10,000→ 186,528 totalExercise: $6.80Exp: 2026-12-15→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2025-03-24$6.80/sh+10,000$68,050→ 18,078 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024.
- [F2]This transaction was executed in two trades at $14.00. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
- [F3]This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of December 16, 2019, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
- [F4]Not applicable.